本研究では、ICIの作用部位であるエフェクターT細胞、NK細胞の特性変化について、末梢血を試料として治療効果や副作用との関連性を評価した。ROC解析より、好中球数およびCD28陽性CD8陽性T細胞数は、non-PDの予測率がそれぞれ81.8%、72.7%であった。ICI治療早期における好中球数やCD28陽性CD8陽性T細胞は、ICI治療を予測するバイオマーカーとなる可能性がある。
This study was performed to investigate the association of host factors including peripheral blood cell characteristics with the PD-1/PD-L1 therapy. A total of 20 patients were enrolled. The number of patients administrated pembrolizumab, nivolumab, and atezolizumab was 12, 7 and 1, respectively. Twelve patients were diagnosed as progressive disease (PD), and 8 were non-PD. All 6 female patients were diagnosed as PD. In the blood sample obtained within 3 weeks from the immune therapy, significantly high CD28 positive CD8+ T lymphocyte counts and low neutrophil counts were observed in the non-PD patients compared with the PD patients. Meanwhile, the distribution of tumor PD-L1 levels, clinical stage of NSCLC, and other immune markers investigated in the non-PD patients were comparable with the PD patients. CD28 positive CD8+ T lymphocyte and neutrophil counts were considered to be possible biomarkers related to the efficacy of PD-1/PD-L1 therapy.